ecteinascidin 743 has been researched along with Thrombopenia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hohenberger, P; Kasper, B; Mathew, M; Pink, D; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Baconnier, M; Blay, JY; Boudou, L; Cassier, PA; Lombard-Bohas, C | 1 |
| Beijnen, JH; Brain, E; Cvitkovic, E; Guzman, C; Hillebrand, MJ; Jimeno, JM; López-Lázaro, L; Math t, RA; Misset, JL; Rosing, H; Schellens, JH; Taamma, A; van Kesteren, C | 1 |
| Brain, E; Cvitkovic, E; Guzman, C; Jimeno, JM; Lopez Lazaro, L; Misset, JL; Riofrio, M; Rosing, H; Taamma, A | 1 |
| Beijnen, JH; Bowman, A; Guzman, C; Hillebrand, MJ; Hoekman, K; Jimeno, J; López-Lázaro, L; Mathôt, RA; Rosing, H; Schellens, JH; Simpson, A; Smyth, J; Twelves, C; van Kesteren, C; Vermorken, JB | 1 |
| Cvetkovic, RS; Figgitt, DP; Plosker, GL | 1 |
2 review(s) available for ecteinascidin 743 and Thrombopenia
| Article | Year |
|---|---|
Trabectedin for the management of soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Controlled Clinical Trials as Topic; Dioxoles; DNA Repair; Female; Humans; Liver; Neutropenia; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2009 |
ET-743.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Humans; Isoquinolines; Liver; Neoplasms; Neutropenia; Survival Analysis; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin | 2002 |
3 trial(s) available for ecteinascidin 743 and Thrombopenia
| Article | Year |
|---|---|
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Drug Therapy, Combination; Female; Gemcitabine; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2015 |
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Neutropenia; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin | 2001 |
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Dioxoles; Fatigue; Female; Half-Life; Humans; Infusions, Intravenous; Isoquinolines; Male; Maximum Tolerated Dose; Middle Aged; Tetrahydroisoquinolines; Thrombocytopenia; Time Factors; Trabectedin; Urochordata | 2002 |
1 other study(ies) available for ecteinascidin 743 and Thrombopenia
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Area Under Curve; Aspartate Aminotransferases; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Isoquinolines; Liver; Male; Middle Aged; Models, Chemical; Neoplasms; Neutropenia; Tetrahydroisoquinolines; Thrombocytopenia; Time Factors; Trabectedin | 2000 |